Implementation of the standard strategy for identification of Ig/TCR targets for minimal residual disease diagnostics in B-cell precursor ALL pediatric patients: Polish experience

Archivum Immunologiae et Therapiae Experimentalis

Volumn 56, Issue 6, 2008, Pages 409-418

  Dawidowska, Małgorzata ^a   Jółkowska, Justyna ^a   Szczepański, Tomasz ^b,c   Derwich, Katarzyna ^d   Wachowiak, Jacek ^d   Witt, Michał ^a,e  

^a INSTITUTE OF HUMAN GENETICS   (Poland)

^b MEDICAL UNIVERSITY OF SILESIA   (Poland)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^e INTERNATIONAL INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Poland)

Author keywords

Acute lymphoblastic leukemia; BIOMED 1; BIOMED 2; Ig TCR gene rearrangements; Minimal residual disease

Indexed keywords

IMMUNOGLOBULIN; T LYMPHOCYTE RECEPTOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; BRAZIL; CHILD; CHILE; CONTROLLED STUDY; FEASIBILITY STUDY; FEMALE; GENE REARRANGEMENT; GENE SEQUENCE; HUMAN; HUMAN TISSUE; ITALY; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; NETHERLANDS; POLAND; POLYMERASE CHAIN REACTION; PRE B LYMPHOCYTE; SEQUENCE HOMOLOGY; WESTERN EUROPE;

ADOLESCENT; B-LYMPHOCYTES; CELL LINE, TUMOR; CHILD; CHILD, PRESCHOOL; EUROPE; FEMALE; GENE REARRANGEMENT; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; INFANT; MALE; MEDICAL ONCOLOGY; NEOPLASM, RESIDUAL; POLAND; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; RECEPTORS, ANTIGEN, T-CELL;

EID: 58549116303     PISSN: 0004069X     EISSN: 16614917     Source Type: Journal    
DOI: 10.1007/s00005-008-0045-y     Document Type: Article

References (33)

1. Barriga F. J., RisueNo C., Patillo J. C., Andrade W., Cabrera M. E., Beressi V., Del Borgo P., Salgado C., Becker A., Campbell M. and Bertin P. (1996): Analysis of the complementary determining region III of the immunoglobulin heavy chain locus in acute lymphoblastic leukemia in Chilean children. Leukemia, 10, 1719-1723.
2. Beishuizen A., de Bruijn M. A., Pongers-Willemse M. J., Verhoeven M. A., van Wering E. R., Hahlen K., Breit T. M., de Bruin-Versteeg S., Hooijkaas H. and van Dongen J. J. (1997): Heterogeneity in junctional regions of immunoglobulin kappa deleting element rearrangements in B cell leukemias: a new molecular target for detection of minimal residual disease. Leukemia, 11, 2200-2207.
3. Berman J. E., Nickerson K. G., Pollock R. R., Barth J. E., Schuurman R. K., Knowles D. M., Chess L. and Alt F. W. (1991): VH gene usage in humans: biased usage of the VH6 gene in immature B lymphoid cells. Eur. J. Immunol., 21, 1311-1314.
4. Brumpt C., Delabesse E., Beldjord K., Davi F., Cayuela J. M., Millien C., Villarese P., Quartier P., Buzyn A., Valensi F. and Macintyre E. (2000): The incidence of clonal T-cell receptor rearrangements in B-cell precursor acute lymphoblastic leukemia varies with age and genotype. Blood, 96, 2254-2261.
5. Cannell P. K., Amlot P., Attard M., Hoffbrand A. V. and Foroni L. (1994): Variable kappa gene rearrangement in lymphoproliferative disorders: an analysis of V kappa gene usage, VJ joining and somatic mutation. Leukemia, 8, 1139-1145.
6. Cave H., Guidal C., Rohrlich P., Delfau M. H., Broyart A., Lescoeur B., Rahimy C., Fenneteau O., Monplaisir N. and d'Auriol L. (1994): Prospective monitoring and quantitation of residual blasts in childhood acute lymphoblastic leukemia by polymerase chain reaction study of delta and gamma T-cell receptor genes. Blood, 83, 1892-1902.
7. Cave H., van der Werff ten Bosch J., Suciu S., Guidal C., Waterkeyn C., Otten J., Bakkus M., Thielemans K., Grandchamp B. and Vilmer E. (1998): Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer-Childhood Leukemia Cooperative Group. N. Engl. J. Med., 339, 591-598.
8. Coyle L. A., Papaioannou M., Yaxley J. C., Chim J. S., Attard M., Hoffbrand A. V. and Foroni L. (1996): Molecular analysis of the leukaemic B cell in adult and childhood acute lymphoblastic leukaemia. Br. J. Haematol., 94, 685-693.
9. Dawidowska M., Derwich K., Szczepanski T., Jolkowska J., van der Velden V. H., Wachowiak J. and Witt M. (2006): Pattern of immunoglobulin and T-cell receptor (Ig/TCR) gene rearrangements in Polish pediatric acute lymphoblastic leukemia patients - implications for RQ-PCR-based assessment of minimal residual disease. Leuk. Res., 30, 1119-1125.
10. Germano G., del Giudice L., Palatron S., Giarin E., Cazzaniga G., Biondi A. and Basso G. (2003): Clonality profile in relapsed precursor-B-ALL children by GeneScan and sequencing analyses. Consequences on minimal residual disease monitoring. Leukemia, 17, 1573-1582.
11. Langerak A. W., Szczepanski T., van der Burg M., Wolvers-Tettero I. L. and van Dongen J. J. (1997): Heteroduplex PCR analysis of rearranged T cell receptor genes for clonality assessment in suspect T cell proliferations. Leukemia, 11, 2192-2199.
12. Li A., Rue M., Zhou J., Wang H., Goldwasser M.A., Neuberg D., Dalton V., Zuckerman D., Lyons C., Silverman L. B., Sallan S. E. and Gribben J. G. (2004): Utilization of Ig heavy chain variable, diversity, and joining gene segments in children with B-lineage acute lymphoblastic leukemia: implications for the mechanisms of VDJ recombination and for pathogenesis. Blood, 103, 4602-4609.
13. Meleshko A. N., Belevtsev M. V., Savitskaja T. V. and Potapnev M. P. (2006): The incidence of T-cell receptor gene rearrangements in childhood B-lineage acute lymphoblastic leukemia is related to immunophenotype and fusion oncogene expression. Leuk. Res., 30, 795-800.
14. Pongers-Willemse M. J., Seriu T., Stolz F., d'Aniello E., Gameiro P., Pisa P., Gonzalez M., Bartram C. R., Panzer-Grumayer E. R., Biondi A., San Miguel J. F. and van Dongen J. J. (1999): Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: report of the BIOMED-1 CONCERTED ACTION: investigation of minimal residual disease in acute leukemia. Leukemia, 13, 110-118.
15. Radwańska U. (1998): Ostra białaczka limfoblastyczna. In Radwańska U. (ed.): Białaczki u dzieci. Volumed, Wrocław, 57-89.
16. Sazawal S., Bhatia K., Gurbuxani S., Singh Arya L., Raina V., Khattar A., Vats T., Magrath I. and Bhargava M. (2000): Pattern of immunoglobulin (Ig) and T-cell receptor (TCR) gene rearrangements in childhood acute lymphoblastic leukemia in India. Leuk. Res., 24, 575-582.
17. Scrideli C. A., Queiroz R. G., Kashima S., Sankarankutty B. O. and Tone L. G. (2004): T cell receptor gamma (TCRG) gene rearrangements in Brazilian children with acute lymphoblastic leukemia: analysis and implications for the study of minimal residual disease. Leuk. Res., 28, 267-273.
18. Scrideli C. A. and Tone L. G. (2006): Ig and TCR gene rearrangements in childhood ALL is there ethnic and socio-economic diversity of rearrangement patterns? Leuk. Res., 30, 1065-1066.
19. Szczepański T., Beishuizen A., Pongers-Willemse M. J., Hahlen K., Van Wering E. R., Wijkhuijs A. J., Tibbe G. J., De Bruijn M. A. and Van Dongen J. J. (1999): Cross-lineage T cell receptor gene rearrangements occur in more than ninety percent of childhood precursor-B acute lymphoblastic leukemias: alternative PCR targets for detection of minimal residual disease. Leukemia, 13, 196-205.
20. Szczepański T., van der Velden V. H., Hoogeveen P. G., de Bie M., Jacobs D. C., van Wering E. R. and van Dongen J. J. (2004): Vdelta2-Jalpha rearrangements are frequent in precursor-B-acute lymphoblastic leukemia but rare in normal lymphoid cells. Blood, 103, 3798-3804.
21. Szczepański T., Willemse M. J., Brinkhof B., van Wering E. R., van der Burg M. and van Dongen J. J. (2002): Comparative analysis of Ig and TCR gene rearrangements at diagnosis and at relapse of childhood precursor-B-ALL provides improved strategies for selection of stable PCR targets for monitoring of minimal residual disease. Blood, 99, 2315-2323.
22. Szczepański T., Willemse M. J., van Wering E. R., van Weerden J. F., Kamps W. A. and van Dongen J. J. (2001): Precursor-B-ALL with D(H)-J(H) gene rearrangements have an immature immunogenotype with a high frequency of oligoclonality and hyperdiploidy of chromosome 14. Leukemia, 15, 1415-1423.
23. van der Velden V. H., Bruggemann M., Hoogeveen P. G., de Bie M., Hart P. G., Raff T., Pfeifer H., Luschen S., Szczepanski T., van Wering E. R., Kneba M. and van Dongen J. J. (2004): TCRB gene rearrangements in childhood and adult precursor-B-ALL: frequency, applicability as MRD-PCR target, and stability between diagnosis and relapse. Leukemia, 18, 1971-1980.
24. van der Velden V. H., Cazzaniga G., Schrauder A., Hancock J., Bader P., Panzer-Grumayer E. R., Flohr T., Sutton R., Cave H., Madsen H. O., Cayuela J. M., Trka J., Eckert C., Foroni L., Zur Stadt U., Beldjord K., Raff T., van der Schoot C. E. and van Dongen J. J. (2007): Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia, 21, 604-611.
25. van der Velden V. H., Hochhaus A., Cazzaniga G., Szczepanski T., Gabert J. and van Dongen J. J. (2003): Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia, 17, 1013-1034.
26. van der Velden V. H., Joosten S. A., Willemse M. J., van Wering E. R., Lankester A. W., van Dongen J. J. and Hoogerbrugge P. M. (2001): Real-time quantitative PCR for detection of minimal residual disease before allogeneic stem cell transplantation predicts outcome in children with acute lymphoblastic leukemia. Leukemia, 15, 1485-1487.
27. van der Velden V. H., Szczepanski T., Wijkhuijs J. M., Hart P. G., Hoogeveen P. G., Hop W. C., van Wering E. R. and van Dongen J. J. (2003): Age-related patterns of immunoglobulin and T-cell receptor gene rearrangements in precursor-B-ALL: implications for detection of minimal residual disease. Leukemia, 17, 1834-1844.
28. van der Velden V. H., Wijkhuijs J. M., Jacobs D. C., van Wering E. R. and van Dongen J. J. (2002): T cell receptor gamma gene rearrangements as targets for detection of minimal residual disease in acute lymphoblastic leukemia by real-time quantitative PCR analysis. Leukemia, 16, 1372-1380.
29. van der Velden V. H., Willemse M. J., van der Schoot C. E., Hahlen K., van Wering E. R. and van Dongen J. J. (2002): Immunoglobulin kappa deleting element rearrangements in precursor-B acute lymphoblastic leukemia are stable targets for detection of minimal residual disease by real-time quantitative PCR. Leukemia, 16, 928-936.
30. van Dongen J. J., Langerak A. W., Bruggemann M., Evans P. A., Hummel M., Lavender F. L., Delabesse E., Davi F., Schuuring E., Garcia-Sanz R., van Krieken J. H., Droese J., Gonzalez D., Bastard C., White H. E., Spaargaren M., Gonzalez M., Parreira A., Smith J. L., Morgan G. J., Kneba M. and Macintyre E. A. (2003): Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia, 17, 2257-2317.
31. van Dongen J. J., Seriu T., Panzer-Grumayer E. R., Biondi A., Pongers-Willemse M. J., Corral L., Stolz F., Schrappe M., Masera G., Kamps W.A., Gadner H., van Wering E. R., Ludwig W. D., Basso G., de Bruijn M. A., Cazzaniga G., Hettinger K., van der Does-van den Berg A., Hop W. C., Riehm H. and Bartram C. R. (1998): Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet, 352, 1731-1738.
32. Wasserman R., Ito Y., Galili N., Yamada M., Reichard B. A., Shane S., Lange B. and Rovera G. (1992): The pattern of joining (JH) gene usage in the human IgH chain is established predominantly at the B precursor cell stage. J. Immunol., 149, 511-516.
33. Willems P., Verhagen O., Segeren C., Veenhuizen P., Guikema J., Wiemer E., Groothuis L., Jong T. B., Kok H., Bloem A., Bos N., Vellenga E., Mensink E., Sonneveld P., Lokhorst H., van Der Schoot E. and Raymakers R. (2000): Consensus strategy to quantitate malignant cells in myeloma patients is validated in a multicenter study. Belgium-Dutch Hematology-Oncology Group. Blood, 96, 63-70.